Modulo Bio
Modulo Bio is focused on reprogramming the brain's immune system, specifically targeting microglia to develop treatments for neurological conditions. Their innovative platform combines advanced data science, stem cell engineering, and machine learning to understand and manipulate microglial behaviors, aiming to discover effective therapies for brain and central nervous system disorders. With a mission to benefit patients and their families, Modulo Bio is positioned at the forefront of neuroimmune research, leveraging cutting-edge technology to address significant medical challenges.
Modulo Bio
Modulo Bio is focused on reprogramming the brain's immune system, specifically targeting microglia to develop treatments for neurological conditions. Their innovative platform combines advanced data science, stem cell engineering, and machine learning to understand and manipulate microglial behaviors, aiming to discover effective therapies for brain and central nervous system disorders. With a mission to benefit patients and their families, Modulo Bio is positioned at the forefront of neuroimmune research, leveraging cutting-edge technology to address significant medical challenges.
TL;DR
Focus: Reprogramming the brain's immune system (microglia) to discover neuroprotective therapies
Headquarters: San Diego, CA
Founded: 2021
Employees (approx.): 12
Known investors: Initialized Capital; Alzheimer's Drug Discovery Foundation; Cantos; Hawktail Management; Refactor; Builders VC; Bioverge; Spacecadet Ventures; The ALS Association
Reported total funding: USD 23,055,780
Company Overview
Problem Domain
Neurological and central nervous system disorders driven by neuroimmune dysfunction
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
8,000,000 USD
Seed round announced June 1, 2023
4,800,000 USD
Reported strategic investment
500,000 USD
Awarded grant